Study of Magnesium Sulfate in Children With Reduced Bone Density Secondary to Chronic Cholestatic Liver Disease

Not Applicable

Completed

• Conditions: Alagille Syndrome; Cholestasis; Biliary Atresia

• Registration Number: NCT00007033
• Lead Sponsor: National Center for Research Resources (NCRR)

Brief Summary

OBJECTIVES:

I. Determine the role of magnesium deficiency in the pathogenesis of decreased serum vitamin D and reduced bone density in children with chronic cholestatic liver disease.

Detailed Description

PROTOCOL OUTLINE:

Patients receive magnesium sulfate IV over 1 hour on day 3. Patients then receive oral magnesium gluconate supplementation daily. Treatment with magnesium sulfate repeats once at 3-6 months.

Study Timeline

• Study Start: 2000-10
• Study First Submitted: 2000-12-06
• Study First Submitted QC: 2000-12-06
• Study First Posted: 2000-12-07
• Status Verified: 2002-04
• Last Update Submitted: 2009-01-21
• Last Update Posted: 2009-01-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

Children's Hospital Medical Center - Cincinnati; 🇺🇸 Cincinnati, Ohio, United States